^
Association details:
Evidence:
Evidence Level:
Resistant: D – Preclinical
Source:
Title:

Upregulation of USP22 and ABCC1 during Sorafenib Treatment of Hepatocellular Carcinoma Contribute to Development of Resistance

Published date:
02/11/2022
Excerpt:
Our findings indicate that upregulation of USP22 and ABCC1 expression during treatment contribute to sorafenib resistance in HCC cells…
DOI:
10.3390/cells11040634